#1 Clinical Trials Search in Europe

Garadacimab

Garadacimab, a promising new drug, is currently being studied in clinical trials for its potential in treating Idiopathic Pulmonary Fibrosis (IPF). This article explores the ongoing research, focusing on a phase 2a study that examines the safety, how the body processes the drug, and how it affects the body in patients with IPF. The trial aims to provide valuable insights into Garadacimab’s potential as a treatment option for this challenging lung condition.

Table of Contents

What is Garadacimab?

Garadacimab, also known as CSL312, is a new medication being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). It is classified as a Factor XIIa antagonist monoclonal antibody[1]. This means it’s a type of drug that targets and blocks a specific protein in the body called Factor XIIa, which is involved in certain biological processes.

Target Condition: Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease that causes scarring (fibrosis) of the lungs. The term “idiopathic” means the cause is unknown. This scarring makes it difficult for the lungs to work properly, leading to breathing problems that worsen over time[1].

Clinical Trial Details

A clinical trial is currently underway to study Garadacimab in patients with IPF. This trial is known as a Phase 2a study, which means it’s an early stage of testing the drug in humans. Here are some key details about the trial[1]:

  • It’s a randomized study, meaning participants are randomly assigned to either receive Garadacimab or a placebo.
  • It’s double-blind, which means neither the patients nor the doctors directly involved know who is receiving the real drug or the placebo.
  • It’s placebo-controlled, comparing Garadacimab to an inactive substance (placebo) to determine its effectiveness.
  • The study is designed to assess the safety, pharmacokinetics (how the body processes the drug), and pharmacodynamics (how the drug affects the body) of Garadacimab in IPF patients.

Administration and Dosing

In this study, Garadacimab is being administered in two ways[1]:

  1. Intravenous (IV) loading dose: This is an initial dose given directly into the vein.
  2. Subcutaneous (SC) doses: Following the IV dose, patients receive three doses that are injected under the skin.

This combination of IV and SC dosing is likely designed to quickly achieve an effective level of the drug in the body (with the IV dose) and then maintain that level over time (with the SC doses).

Safety Measures

The study is closely monitoring the safety of Garadacimab. Some key safety measures include[1]:

  • Serious Adverse Events (SAEs): These are any serious health issues that occur during the study, whether or not they’re believed to be caused by the drug.
  • Adverse Events of Special Interest (AESIs): The study is particularly watching for:
    • Unusual bleeding events
    • Blood clots (thromboembolic events)
    • Severe allergic reactions (including anaphylaxis)
  • Anti-Drug Antibodies (ADAs): The study is checking if patients’ bodies develop antibodies against Garadacimab, which could affect its effectiveness or safety.
  • Laboratory Tests: Any significant changes in lab test results that are reported as side effects are being monitored.

Effectiveness Evaluation

While the primary focus of this study is on safety, researchers are also looking at how Garadacimab affects the body. They’re measuring[1]:

  • Drug Levels in the Blood: This helps understand how the body processes Garadacimab.
  • FXIIa-mediated Kallikrein Activity: This is a measure of how well Garadacimab is blocking its target in the body.

These measurements will help researchers determine if Garadacimab is working as expected and guide future studies on its effectiveness in treating IPF.

Aspect Details
Drug Name Garadacimab (also known as CSL312)
Drug Type Factor XIIa antagonist monoclonal antibody
Condition Studied Idiopathic Pulmonary Fibrosis (IPF)
Study Phase Phase 2a
Study Design Randomized, double-blind, placebo-controlled
Administration Method Intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses
Primary Outcomes Safety assessment, including adverse events and anti-drug antibodies
Secondary Outcomes Pharmacokinetics and pharmacodynamics measurements
Study Duration Up to 14 weeks after treatment

FAQ

  • What is Garadacimab? Garadacimab is a drug being studied for the treatment of Idiopathic Pulmonary Fibrosis. It's also known as a Factor XIIa antagonist monoclonal antibody or CSL312. The drug is administered both intravenously (through a vein) and subcutaneously (under the skin) in the clinical trial.
  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess the safety, pharmacokinetics (how the body processes the drug), and pharmacodynamics (how the drug affects the body) of Garadacimab in patients with Idiopathic Pulmonary Fibrosis.
  • How is the trial designed? The trial is designed as a phase 2a, multicenter, randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to either receive Garadacimab or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
  • What are the primary outcomes being measured in this trial? The primary outcomes include the number and percentage of participants experiencing serious adverse events, adverse events of special interest, and the development of anti-drug antibodies. The study also looks at clinically significant abnormalities in laboratory assessments reported as adverse events.
  • How long does the trial last? The trial lasts up to 14 weeks after treatment. Participants receive an initial intravenous dose followed by three subcutaneous doses. Measurements are taken at various time points, including Day 36, Day 64, and Day 92 after the first treatment.

Ongoing Clinical Trials on Garadacimab

  • Safety Study of Switching from Current Treatment to Garadacimab in Patients Age 12 and Older with Hereditary Angioedema

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany

  • Long-term safety study of garadacimab (CSL312) for prevention of hereditary angioedema attacks

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Hungary The Netherlands Spain

  • Study on the Safety and Effects of Garadacimab for Preventing Hereditary Angioedema in Children Aged 2 to 11

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease characterized by scarring (fibrosis) of the lungs, which causes difficulty breathing. The term 'idiopathic' means the cause is unknown.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes disability or permanent damage, or is otherwise medically significant.
  • Anti-Drug Antibodies (ADAs): Antibodies produced by the body's immune system in response to a drug, which can potentially reduce the drug's effectiveness or cause adverse reactions.
  • Factor XIIa antagonist: A substance that blocks or inhibits the action of Factor XIIa, an enzyme involved in blood clotting and inflammation.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to treat various diseases, including some types of cancer.

References

  1. https://clinicaltrials.gov/study/NCT05130970